However, regarding anti-IL-6 treatment with tocilizumab of patients with active RA despite previous csDMARDS and/or bDMARDs, no significant changes in systemic resistin along with leptin and ghrelin during follow-up after 12 months were observed in contrast to adiponectin [52]. This evidence concerns the gene IL6 and rheumatoid arthritis.